| |||||||||||||||
- Description
- Phenotype
- Genes & alleles
- Genotyping
- Health & husbandry
- References
- Purchasing information
- Terms of Use
Description
Strain Information
Former Names FVB/N-Tg(MMTVPyVT)634Mul/J (Changed: 15-DEC-04 ) Type Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Mating System Noncarrier x Hemizygote (Female x Male) Species laboratory mouse Generation N18+F3 (30-DEC-08) Donating Investigator William Muller, McGill University Appearance
albino
Related Genotype: Tyrc/TyrcImportant Note
This strain is homozygous for the retinal degeneration allele Pde6brd1.Description
Mice carrying the (MMTV-PyVT) transgene are viable, but show loss of lactational ability coincident with transgene expression. Female carriers develop palpable mammary tumors as early as 5 weeks of age. Adenocarcinomas arise in virgin and breeder females as well as males, which are multifocal, highly fibrotic, and involve the entire mammary fat pad. Males also develop adenocarcinoma of the seminal vesicles and hemangiomas. Pulmonary metastases are observed in 80-94% of tumor-bearing female mice. Transgene expression is detected at high levels in male and female mammary glands. Lower levels are detected in salivary gland, seminal vesicles, ovaries, and lungs (believed to be the result of pulmonary metastases).
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| 001800 FVB/NJ | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying Pde6brd1 allele
View Strains carrying Pde6brd1 (74 strains)
004297 B6.CXB1-Pde6brd10/J 002802 C3.BLiA Pde6b+-Krd/J 001979 C3A.BLiA-Pde6b+.O20-Prph2Rd2/J 001912 C3A.BLiA-Pde6b+/J 003648 C3Sn.BLiA-Pde6b+/Dn 004766 C57BL/6J-Pde6brd1-2J/J 004828 FVB.129P2-Pde6b+ Tyrc-ch/AntJ 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J
004997 B6.Cg-Tg(MMTV-TGFBR2)7Hlm/J 002618 B6.Cg-Tg(MMTVtTA)1Mam/J 007962 B6.FVB-Tg(MMTV-neu/OT-I/OT-II)CBnel Tg(Trp53R172H)8512Jmr/J 002375 B6;D2-Tg(MMTVTGFB1)46Hlm/J 002459 B6D2-Tg(MMTVTGFA)254Rjc/J 002373 B6D2-Tg(MMTVTGFA)29Rjc/J 002870 B6SJL-Tg(Wnt1)1Hev/J 005038 FVB-Tg(MMTV-Erbb2)NK1Mul/J 004363 FVB.Cg-Tg(MMTV-vHaras)SH1Led/J 002953 FVB.Cg-Tg(MMTVTGFA)254Rjc/J 002934 FVB.Cg-Tg(Wnt1)1Hev/J 002437 FVB/N-Tg(MMTV-Notch4)3Rnc/J 002376 FVB/N-Tg(MMTVneu)202Mul/J 002933 FVB/NJ-Tg(MMTVTGFB1)46Hlm/J 003690 STOCK Tg(MMTV-Cdc37)1Stp/J 003337 STOCK Tg(MMTV-PIP)1Shu/J 003551 STOCK Tg(MMTV-cre)1Mam/J 003553 STOCK Tg(MMTV-cre)4Mam/J
Phenotype
Phenotype Information
assigned by genotype
Tg(MMTV-PyVT)634Mul/0
FVB/N-Tg(MMTV-PyVT)634Mul
- tumorigenesis
- increased metastatic potential (MGI Ref ID J:48285)
- pulmonary metastases are observed in 94% of tumor-bearing female mice and 80% of tumor-bearing male mice
- mammary adenocarcinoma (MGI Ref ID J:48285)
- mammary tumors appear in males and females with 100% penetrance by 40 days of age
- all female carriers develop palpable mammary tumors by 5 weeks of age; male carriers also develop these tumors with a later age of onset (median 83 days of age)
- tumors are multifocal, highly fibrotic, and involved the entire mammary fat pad
- endocrine/exocrine gland phenotype
- abnormal lactation (MGI Ref ID J:46460)
- inability to lactate from the time of the first pregnancy
- reproductive system phenotype
- abnormal lactation (MGI Ref ID J:46460)
- inability to lactate from the time of the first pregnancy
Tg(MMTV-PyVT)634Mul/0
FVB/N-Tg(MMTV-PyVT)634Mul/J
- tumorigenesis
- mammary gland tumor (MGI Ref ID J:147458)
- mice develop mammary gland tumors with a median age of tumor latency of 66 days in females and 133.5 days in males unlike wild-type mice
- respiratory system phenotype
- increased lung weight (MGI Ref ID J:147458)
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Tg(MMTV-PyVT)634Mul/0
multiple strains
- tumorigenesis
- decreased metastatic potential (MGI Ref ID J:48854)
- in F1 FVB/N mice crossed to the RF/J, C58/J, C57BR/cdJ, NZB/B1NJ, I/LnJ, DBA/2J, KK/HiJ, MOLF/Ei, SEA/GnJ, NZW/LacJ, or CE/J strains, an decrease in pulmonary metastatic index is seen
- increased metastatic potential (MGI Ref ID J:48854)
- in F1 FVB/N mice crossed to the AKR/J strain, an increase in pulmonary metastatic index is seen
- increased resistance to mammary neoplasm (MGI Ref ID J:48854)
- in F1 FVB/N mice crossed to the P/J, DBA/1J, NZW/LacJ, C57BL/6NIcr, CAST/Ei, NOD/LtJ, CBA/CaJ, SWR/J, AKR/J, BUB/BnJ, ST/J, KK/HiJ, or MOLF/Ei strains, an increased latency of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain
- mammary adenocarcinoma (MGI Ref ID J:48854)
- in F1 FVB/N mice crossed to either the I/LnJ or C58/J strains, an acceleration of the onset of the appearance of primary mammary tumors is seen compared to the inbred FVB/N strain
Tg(MMTV-PyVT)634Mul/0
involves: 129 * C57BL/6 * FVB/N
- tumorigenesis
- mammary adenocarcinoma (MGI Ref ID J:117336)
- all female virgin mice develop cancer tumors in the breast by 14 weeks of age
Tg(MMTV-PyVT)634Mul/0
involves: C57BL/6 * FVB/N
Genes & Alleles
Gene & Allele Information
| Allele Symbol | Tg(MMTV-PyVT)634Mul | ||
|---|---|---|---|
| Allele Name | transgene insertion 634, William Muller | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | MMTV-PyMT; MMTV-PyVmT; PyMT; PyV-mT; PyVT; Tg(MMTVPyVT)634Mul; TgN(MMTVPyVT)634Mul; | ||
| Mutation Made By | William Muller, McGill University | ||
| Strain of Origin | FVB/N | ||
| Expressed Gene | PyVT, Polyoma virus middle T antigen, polyoma virus | ||
| Promoter | MMTV, Mouse Mammary Tumor Virus, MMTV | ||
| General Note |
Additional lines produced include lines 121, 196, 235, 654, 668, 670. These mice are used to study metastatic disease. | ||
| Molecular Note | This transgene expresses polyoma virus middle T antigen under the control of the mouse mammary tumor virus LTR. Expression of this transgene was detected at high levels in male and female mammary glands. Other expression sites include salivary gland, seminal vesicles, ovaries, and lung. [MGI Ref ID J:46460] | ||
| Allele Symbol | Pde6brd1 | ||
| Allele Name | retinal degeneration 1 | ||
| Allele Type | Spontaneous | ||
| Common Name(s) | Pdebrd1; rd; rd-1; rd1; rodless retina; | ||
Genotyping
Genotyping Information
Genotyping Protocols
Tg(MMTV-PyVT)634Mul, MCA, vers. 2
Tg(MMTV-PyVT)634Mul, STD PCR, vers. 1
Helpful Links
Genotyping resources and troubleshooting
References
References
Selected Reference(s)
Guy CT; Cardiff RD; Muller WJ. 1992. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 12(3):954-61. [PubMed: 1312220] [MGI Ref ID J:46460]
Additional References
Le Voyer T; Rouse J; Lu Z; Lifsted T; Williams M; Hunter KW. 2001. Three loci modify growth of a transgene-induced mammary tumor: suppression of proliferation associated with decreased microvessel density. Genomics 74(3):253-61. [PubMed: 11414753] [MGI Ref ID J:70229]
Muraoka RS; Dumont N; Ritter CA; Dugger TC; Brantley DM; Chen J; Easterly E; Roebuck LR; Ryan S; Gotwals PJ; Koteliansky V; Arteaga CL. 2002. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109(12):1551-9. [PubMed: 12070302] [MGI Ref ID J:86709]
Politi K; Kljuic A; Szabolcs M; Fisher P; Ludwig T; Efstratiadis A. 2004. 'Designer' tumors in mice. Oncogene 23(8):1558-65. [PubMed: 14661057] [MGI Ref ID J:87544]
Saez E; Rosenfeld J; Livolsi A; Olson P; Lombardo E; Nelson M; Banayo E; Cardiff RD; Izpisua-Belmonte JC; Evans RM. 2004. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev 18(5):528-40. [PubMed: 15037548] [MGI Ref ID J:89019]
Tg(MMTV-PyVT)634Mul relatedAl Masri A; Gendler SJ. 2005. Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis. Oncogene 24(38):5799-808. [PubMed: 15897873] [MGI Ref ID J:101766]
Albright CD; Salganik RI; Van Dyke T. 2004. Dietary depletion of vitamin e and vitamin a inhibits mammary tumor growth and metastasis in transgenic mice. J Nutr 134(5):1139-44. [PubMed: 15113960] [MGI Ref ID J:90173]
Almholt K; Lund LR; Rygaard J; Nielsen BS; Dano K; Romer J; Johnsen M. 2005. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 113(4):525-32. [PubMed: 15472905] [MGI Ref ID J:94645]
Basu GD; Pathangey LB; Tinder TL; Lagioia M; Gendler SJ; Mukherjee P. 2004. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2(11):632-42. [PubMed: 15561779] [MGI Ref ID J:94659]
Basu GD; Tinder TL; Bradley JM; Tu T; Hattrup CL; Pockaj BA; Mukherjee P. 2006. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 177(4):2391-402. [PubMed: 16888001] [MGI Ref ID J:138387]
Bentires-Alj M; Neel BG. 2007. Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. Cancer Res 67(6):2420-4. [PubMed: 17347513] [MGI Ref ID J:120339]
Bierie B; Stover DG; Abel TW; Chytil A; Gorska AE; Aakre M; Forrester E; Yang L; Wagner KU; Moses HL. 2008. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 68(6):1809-19. [PubMed: 18339861] [MGI Ref ID J:133311]
Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J. 2008. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118(1):64-78. [PubMed: 18079969] [MGI Ref ID J:130805]
Bugge TH; Lund LR; Kombrinck KK; Nielsen BS; Holmback K; Drew AF; Flick MJ; Witte DP; Dano K; Degen JL. 1998. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16(24):3097-104. [PubMed: 9671388] [MGI Ref ID J:48285]
Cao Y; Luo JL; Karin M. 2007. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci U S A 104(40):15852-7. [PubMed: 17890319] [MGI Ref ID J:125555]
Cheng AM; Saxton TM; Sakai R; Kulkarni S; Mbamalu G; Vogel W; Tortorice CG; Cardiff RD; Cross JC; Muller WJ; Pawson T. 1998. Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell 95(6):793-803. [PubMed: 9865697] [MGI Ref ID J:51424]
Cozma D; Lukes L; Rouse J; Qiu TH; Liu ET; Hunter KW. 2002. A bioinformatics-based strategy identifies c-Myc and Cdc25A as candidates for the Apmt mammary tumor latency modifiers. Genome Res 12(6):969-75. [PubMed: 12045150] [MGI Ref ID J:77063]
Cuevas BD; Winter-Vann AM; Johnson NL; Johnson GL. 2006. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer. Oncogene 25(36):4998-5010. [PubMed: 16568086] [MGI Ref ID J:112298]
Curino AC; Engelholm LH; Yamada SS; Holmbeck K; Lund LR; Molinolo AA; Behrendt N; Nielsen BS; Bugge TH. 2005. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J Cell Biol 169(6):977-85. [PubMed: 15967816] [MGI Ref ID J:99636]
Dadachova E; Nguyen A; Lin EY; Gnatovskiy L; Lu P; Pollard JW. 2005. Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammary cancer in a mouse model remarkably inhibited tumor growth. Nucl Med Biol 32(7):695-700. [PubMed: 16243644] [MGI Ref ID J:103586]
Davie SA; Maglione JE; Manner CK; Young D; Cardiff RD; MacLeod CL; Ellies LG. 2007. Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res 16(2):193-201. [PubMed: 17206489] [MGI Ref ID J:121391]
De Palma M; Mazzieri R; Politi LS; Pucci F; Zonari E; Sitia G; Mazzoleni S; Moi D; Venneri MA; Indraccolo S; Falini A; Guidotti LG; Galli R; Naldini L. 2008. Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14(4):299-311. [PubMed: 18835032] [MGI Ref ID J:140090]
Dong D; Ni M; Li J; Xiong S; Ye W; Virrey JJ; Mao C; Ye R; Wang M; Pen L; Dubeau L; Groshen S; Hofman FM; Lee AS. 2008. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res 68(2):498-505. [PubMed: 18199545] [MGI Ref ID J:131417]
Du Z; Podsypanina K; Huang S; McGrath A; Toneff MJ; Bogoslovskaia E; Zhang X; Moraes RC; Fluck M; Allred DC; Lewis MT; Varmus HE; Li Y. 2006. Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models. Proc Natl Acad Sci U S A 103(46):17396-401. [PubMed: 17090666] [MGI Ref ID J:117125]
Ellies LG. 2003. PyV-mT-induced parotid gland hyperplasia as detected by altered lectin reactivity is not modulated by inducible nitric oxide deficiency. Arch Oral Biol 48(6):415-22. [PubMed: 12749913] [MGI Ref ID J:84218]
Ellies LG; Fishman M; Hardison J; Kleeman J; Maglione JE; Manner CK; Cardiff RD; MacLeod CL. 2003. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int J Cancer 106(1):1-7. [PubMed: 12794750] [MGI Ref ID J:84004]
Emtage PC; Wan Y; Hitt M; Graham FL; Muller WJ; Zlotnik A; Gauldie J. 1999. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models [see comments] Hum Gene Ther 10(5):697-709. [PubMed: 10210138] [MGI Ref ID J:54403]
Eubank TD ; Roberts RD ; Khan M ; Curry JM ; Nuovo GJ ; Kuppusamy P ; Marsh CB. 2009. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res 69(5):2133-40. [PubMed: 19223554] [MGI Ref ID J:146607]
Fantozzi A; Christofori G. 2006. Mouse models of breast cancer metastasis. Breast Cancer Res 8(4):212. [PubMed: 16887003] [MGI Ref ID J:116013]
Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL. 2005. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 65(6):2296-302. [PubMed: 15781643] [MGI Ref ID J:97162]
Gordon RR; Hunter KW; La Merrill M; Sorensen P; Threadgill DW; Pomp D. 2008. Genotype X diet interactions in mice predisposed to mammary cancer: II. Tumors and metastasis. Mamm Genome 19(3):179-89. [PubMed: 18288525] [MGI Ref ID J:136011]
Gordon RR; Hunter KW; Sorensen P; Pomp D. 2008. Genotype x diet interactions in mice predisposed to mammary cancer. I. Body weight and fat. Mamm Genome 19(3):163-78. [PubMed: 18286334] [MGI Ref ID J:132804]
Graham RA; Morris JR; Cohen EP; Taylor-Papadimitriou J. 2001. Up-regulation of MUC1 in mammary tumors generated in a double-transgenic mouse expressing human MUC1 cDNA, under the control of 1.4-kb 5' MUC1 promoter sequence and the middle T oncogene, expressed from the MMTV promoter. Int J Cancer 92(3):382-7. [PubMed: 11291075] [MGI Ref ID J:68466]
Granovsky M; Fata J; Pawling J; Muller WJ; Khokha R; Dennis JW. 2000. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med 6(3):306-12. [PubMed: 10700233] [MGI Ref ID J:60960]
Guy CT; Muthuswamy SK; Cardiff RD; Soriano P; Muller WJ. 1994. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 8(1):23-32. [PubMed: 7507074] [MGI Ref ID J:72125]
Hakem A; Sanchez-Sweatman O; You-Ten A; Duncan G; Wakeham A; Khokha R; Mak TW. 2005. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 19(17):1974-9. [PubMed: 16107613] [MGI Ref ID J:100482]
Hariri M; Wood GA; DiGrappa MA; MacPherson M; Backman SA; Yaffe MJ; Mak TW; Boyd NF; Khokha R. 2004. Experimental manipulation of radiographic density in mouse mammary gland. Breast Cancer Res 6(5):R540-5. [PubMed: 15318935] [MGI Ref ID J:92894]
Hebbard LW; Garlatti M; Young LJ; Cardiff RD; Oshima RG; Ranscht B. 2008. T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res 68(5):1407-16. [PubMed: 18316604] [MGI Ref ID J:132759]
Hedlund M; Ng E; Varki A; Varki NM. 2008. alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res 68(2):388-94. [PubMed: 18199532] [MGI Ref ID J:131420]
Hodgson JG; Malek T; Bornstein S; Hariono S; Ginzinger DG; Muller WJ; Gray JW. 2005. Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling. Cancer Res 65(21):9695-704. [PubMed: 16266989] [MGI Ref ID J:102690]
Hulit J; Suyama K; Chung S; Keren R; Agiostratidou G; Shan W; Dong X; Williams TM; Lisanti MP; Knudsen K; Hazan RB. 2007. N-cadherin signaling potentiates mammary tumor metastasis via enhanced extracellular signal-regulated kinase activation. Cancer Res 67(7):3106-16. [PubMed: 17409417] [MGI Ref ID J:120832]
Hunter KW; Broman KW; Voyer TL; Lukes L; Cozma D; Debies MT; Rouse J; Welch DR. 2001. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res 61(24):8866-72. [PubMed: 11751410] [MGI Ref ID J:73358]
Husemann Y; Geigl JB; Schubert F; Musiani P; Meyer M; Burghart E; Forni G; Eils R; Fehm T; Riethmuller G; Klein CA. 2008. Systemic spread is an early step in breast cancer. Cancer Cell 13(1):58-68. [PubMed: 18167340] [MGI Ref ID J:131063]
Iyengar P; Espina V; Williams TW; Lin Y; Berry D; Jelicks LA; Lee H; Temple K; Graves R; Pollard J; Chopra N; Russell RG; Sasisekharan R; Trock BJ; Lippman M; Calvert VS; Petricoin EF; Liotta L; Dadachova E; Pestell RG; Lisanti MP; Bonaldo P; Scherer PE. 2005. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 115(5):1163-1176. [PubMed: 15841211] [MGI Ref ID J:98091]
Kouros-Mehr H; Bechis SK; Slorach EM; Littlepage LE; Egeblad M; Ewald AJ; Pai SY; Ho IC; Werb Z. 2008. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 13(2):141-52. [PubMed: 18242514] [MGI Ref ID J:131913]
Kupferman ME; Fini ME; Muller WJ; Weber R; Cheng Y; Muschel RJ. 2000. Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression Am J Pathol 157(6):1777-83. [PubMed: 11106549] [MGI Ref ID J:66129]
Kurpios NA; Sabolic NA; Shepherd TG; Fidalgo GM; Hassell JA. 2003. Function of PEA3 Ets transcription factors in mammary gland development and oncogenesis. J Mammary Gland Biol Neoplasia 8(2):177-90. [PubMed: 14635793] [MGI Ref ID J:87017]
La Merrill M; Baston DS; Denison MS; Birnbaum LS; Pomp D; Threadgill DW. 2009. Mouse breast cancer model-dependent changes in metabolic syndrome-associated phenotypes caused by maternal dioxin exposure and dietary fat. Am J Physiol Endocrinol Metab 296(1):E203-10. [PubMed: 18840765] [MGI Ref ID J:145631]
Lahlou H; Sanguin-Gendreau V; Zuo D; Cardiff RD; McLean GW; Frame MC; Muller WJ. 2007. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A 104(51):20302-7. [PubMed: 18056629] [MGI Ref ID J:141541]
Lam JB; Chow KH; Xu A; Lam KS; Liu J; Wong NS; Moon RT; Shepherd PR; Cooper GJ; Wang Y. 2009. Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities. PLoS ONE 4(3):e4968. [PubMed: 19319191] [MGI Ref ID J:147458]
Le Voyer T; Lu Z; Babb J; Lifsted T; Williams M; Hunter K. 2000. An epistatic interaction controls the latency of a transgene-induced mammary tumor. Mamm Genome 11(10):883-9. [PubMed: 11003704] [MGI Ref ID J:64663]
Le Voyer T; Rouse J; Lu Z; Lifsted T; Williams M; Hunter KW. 2001. Three loci modify growth of a transgene-induced mammary tumor: suppression of proliferation associated with decreased microvessel density. Genomics 74(3):253-61. [PubMed: 11414753] [MGI Ref ID J:70229]
Li Y; Welm B; Podsypanina K; Huang S; Chamorro M; Zhang X; Rowlands T; Egeblad M; Cowin P; Werb Z; Tan LK; Rosen JM; Varmus HE. 2003. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A 100(26):15853-8. [PubMed: 14668450] [MGI Ref ID J:87520]
Lifsted T; Le Voyer T; Williams M; Muller W; Klein-Szanto A; Buetow KH ; Hunter KW. 1998. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 77(4):640-4. [PubMed: 9679770] [MGI Ref ID J:48854]
Lin EY; Jones JG; Li P; Zhu L; Whitney KD; Muller WJ; Pollard JW. 2003. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163(5):2113-26. [PubMed: 14578209] [MGI Ref ID J:86499]
Lin EY; Pollard JW. 2004. Macrophages: modulators of breast cancer progression. Novartis Found Symp 256:158-68; discussion 168-72, 259. [PubMed: 15027489] [MGI Ref ID J:90229]
Liu K; Caldwell SA; Abrams SI. 2005. Cooperative disengagement of Fas and intercellular adhesion molecule-1 function in neoplastic cells confers enhanced colonization efficiency. Cancer Res 65(3):1045-54. [PubMed: 15705906] [MGI Ref ID J:96563]
Lopez JI; Camenisch TD; Stevens MV; Sands BJ; McDonald J; Schroeder JA. 2005. CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res 65(15):6755-63. [PubMed: 16061657] [MGI Ref ID J:100774]
Lukes L; Crawford NP; Walker R; Hunter KW. 2009. The origins of breast cancer prognostic gene expression profiles. Cancer Res 69(1):310-8. [PubMed: 19118016] [MGI Ref ID J:143027]
Luo M; Fan H; Nagy T; Wei H; Wang C; Liu S; Wicha MS; Guan JL. 2009. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res 69(2):466-74. [PubMed: 19147559] [MGI Ref ID J:143710]
Ma Z; Gibson SL; Byrne MA; Zhang J; White MF; Shaw LM. 2006. Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Mol Cell Biol 26(24):9338-51. [PubMed: 17030605] [MGI Ref ID J:117024]
Maglione JE; Moghanaki D; Young LJ; Manner CK; Ellies LG; Joseph SO; Nicholson B; Cardiff RD; MacLeod CL. 2001. Transgenic Polyoma middle-T mice model premalignant mammary disease. Cancer Res 61(22):8298-305. [PubMed: 11719463] [MGI Ref ID J:72996]
Man AK; Young LJ; Tynan JA; Lesperance J; Egeblad M; Werb Z; Hauser CA; Muller WJ; Cardiff RD; Oshima RG. 2003. Ets2-dependent stromal regulation of mouse mammary tumors. Mol Cell Biol 23(23):8614-25. [PubMed: 14612405] [MGI Ref ID J:86530]
Maroulakou IG; Oemler W; Naber SP; Tsichlis PN. 2007. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 67(1):167-77. [PubMed: 17210696] [MGI Ref ID J:117336]
Martin MD; Carter KJ; Jean-Philippe SR; Chang M; Mobashery S; Thiolloy S; Lynch CC; Matrisian LM; Fingleton B. 2008. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 68(15):6251-9. [PubMed: 18676849] [MGI Ref ID J:140033]
Moadel RM; Nguyen AV; Lin EY; Lu P; Mani J; Blaufox MD; Pollard JW; Dadachova E. 2003. Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer. Breast Cancer Res 5(6):R199-205. [PubMed: 14580255] [MGI Ref ID J:86497]
Muraoka RS; Dumont N; Ritter CA; Dugger TC; Brantley DM; Chen J; Easterly E; Roebuck LR; Ryan S; Gotwals PJ; Koteliansky V; Arteaga CL. 2002. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 109(12):1551-9. [PubMed: 12070302] [MGI Ref ID J:86709]
Nagle JA; Ma Z; Byrne MA; White MF; Shaw LM. 2004. Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol 24(22):9726-35. [PubMed: 15509777] [MGI Ref ID J:94107]
Neznanov N; Man AK; Yamamoto H; Hauser CA; Cardiff RD; Oshima RG. 1999. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. Cancer Res 59(17):4242-6. [PubMed: 10485465] [MGI Ref ID J:57272]
Nguyen A; Burack WR; Stock JL; Kortum R; Chaika OV; Afkarian M; Muller WJ; Murphy KM; Morrison DK; Lewis RE; McNeish J; Shaw AS. 2002. Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. Mol Cell Biol 22(9):3035-45. [PubMed: 11940661] [MGI Ref ID J:75739]
Niemeyer CC; Spencer-Dene B; Wu JX; Adamson ED. 1999. Preneoplastic mammary tumor markers: Cripto and Amphiregulin are overexpressed in hyperplastic stages of tumor progression in transgenic mice. Int J Cancer 81(4):588-91. [PubMed: 10225449] [MGI Ref ID J:54862]
Ojalvo LS; King W; Cox D; Pollard JW. 2009. High-density gene expression analysis of tumor-associated macrophages from mouse mammary tumors. Am J Pathol 174(3):1048-64. [PubMed: 19218341] [MGI Ref ID J:146811]
Partridge EA; Le Roy C; Di Guglielmo GM; Pawling J; Cheung P; Granovsky M; Nabi IR; Wrana JL; Dennis JW. 2004. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306(5693):120-4. [PubMed: 15459394] [MGI Ref ID J:93100]
Peace BE; Toney-Earley K; Collins MH; Waltz SE. 2005. Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res 65(4):1285-93. [PubMed: 15735014] [MGI Ref ID J:96786]
Pedersen TX; Pennington CJ; Almholt K; Christensen IJ; Nielsen BS; Edwards DR; Romer J; Dano K; Johnsen M. 2005. Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis 26(7):1233-40. [PubMed: 15760918] [MGI Ref ID J:99389]
Politi K; Kljuic A; Szabolcs M; Fisher P; Ludwig T; Efstratiadis A. 2004. 'Designer' tumors in mice. Oncogene 23(8):1558-65. [PubMed: 14661057] [MGI Ref ID J:87544]
Provenzano PP; Inman DR; Eliceiri KW; Beggs HE; Keely PJ. 2008. Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer. Am J Pathol 173(5):1551-65. [PubMed: 18845837] [MGI Ref ID J:141117]
Pylayeva Y; Gillen KM; Gerald W; Beggs HE; Reichardt LF; Giancotti FG. 2009. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 119(2):252-66. [PubMed: 19147981] [MGI Ref ID J:145974]
Qin L; Liao L; Redmond A; Young L; Yuan Y; Chen H; O'Malley BW; Xu J. 2008. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol 28(19):5937-50. [PubMed: 18644862] [MGI Ref ID J:140358]
Qin L; Liu Z; Chen H; Xu J. 2009. The steroid receptor coactivator-1 regulates twist expression and promotes breast cancer metastasis. Cancer Res 69(9):3819-27. [PubMed: 19383905] [MGI Ref ID J:148269]
Qiu TH; Chandramouli GV; Hunter KW; Alkharouf NW; Green JE; Liu ET. 2004. Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res 64(17):5973-81. [PubMed: 15342376] [MGI Ref ID J:92401]
Rauh MJ; Blackmore V; Andrechek ER; Tortorice CG; Daly R; Lai VK; Pawson T; Cardiff RD; Siegel PM; Muller WJ. 1999. Accelerated mammary tumor development in mutant polyomavirus middle T transgenic mice expressing elevated levels of either the Shc or Grb2 adapter protein. Mol Cell Biol 19(12):8169-79. [PubMed: 10567542] [MGI Ref ID J:58608]
Richard S; Vogel G; Huot ME; Guo T; Muller WJ; Lukong KE. 2008. Sam68 haploinsufficiency delays onset of mammary tumorigenesis and metastasis. Oncogene 27(4):548-56. [PubMed: 17621265] [MGI Ref ID J:132092]
Ritland SR; Rowse GJ; Chang Y; Gendler SJ. 1997. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Cancer Res 57(16):3520-5. [PubMed: 9270023] [MGI Ref ID J:72134]
Robinson GW; Wagner KU; Hennighausen L. 2001. Functional mammary gland development and oncogene-induced tumor formation are not affected by the absence of the retinoblastoma gene. Oncogene 20(48):7115-9. [PubMed: 11704837] [MGI Ref ID J:73006]
Rosner A; Miyoshi K; Landesman-Bollag E; Xu X; Seldin DC; Moser AR; MacLeod CL; Shyamala G; Gillgrass AE; Cardiff RD. 2002. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 161(3):1087-97. [PubMed: 12213737] [MGI Ref ID J:78873]
Sanders S; Thorgeirsson SS. 2000. Promotion of hepatocarcinogenesis by phenobarbital in c-myc/TGF-alpha transgenic mice. Mol Carcinog 28(3):168-73. [PubMed: 10942533] [MGI Ref ID J:64633]
Schoeffner DJ; Matheny SL; Akahane T; Factor V; Berry A; Merlino G; Thorgeirsson UP. 2005. VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Lab Invest 85(5):608-23. [PubMed: 15765121] [MGI Ref ID J:98204]
Shepard CR; Kassis J; Whaley DL; Kim HG; Wells A. 2007. PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene 26(21):3020-6. [PubMed: 17130835] [MGI Ref ID J:122884]
Spicer AP; Rowse GJ; Lidner TK; Gendler SJ. 1995. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem 270(50):30093-101. [PubMed: 8530414] [MGI Ref ID J:30128]
Stewart TJ; Abrams SI. 2007. Altered immune function during long-term host-tumor interactions can be modulated to retard autochthonous neoplastic growth. J Immunol 179(5):2851-9. [PubMed: 17709499] [MGI Ref ID J:128726]
Stockmann C; Doedens A; Weidemann A; Zhang N; Takeda N; Greenberg JI; Cheresh DA; Johnson RS. 2008. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456(7223):814-8. [PubMed: 18997773] [MGI Ref ID J:143170]
Tehranian A; Morris DW; Min BH; Bird DJ; Cardiff RD; Barry PA. 1996. Neoplastic transformation of prostatic and urogenital epithelium by the polyoma virus middle T gene. Am J Pathol 149(4):1177-91. [PubMed: 8863667] [MGI Ref ID J:101640]
Trimboli AJ; Fukino K; de Bruin A; Wei G; Shen L; Tanner SM; Creasap N; Rosol TJ; Robinson ML; Eng C; Ostrowski MC; Leone G. 2008. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res 68(3):937-45. [PubMed: 18245497] [MGI Ref ID J:131862]
Ursini-Siegel J; Hardy WR; Zuo D; Lam SH; Sanguin-Gendreau V; Cardiff RD; Pawson T; Muller WJ. 2008. ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J 27(6):910-20. [PubMed: 18273058] [MGI Ref ID J:133325]
Vasiljeva O; Korovin M; Gajda M; Brodoefel H; Bojic L; Kruger A; Schurigt U; Sevenich L; Turk B; Peters C; Reinheckel T. 2008. Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 27(30):4191-9. [PubMed: 18345026] [MGI Ref ID J:138505]
Vasiljeva O; Papazoglou A; Kruger A; Brodoefel H; Korovin M; Deussing J; Augustin N; Nielsen BS; Almholt K; Bogyo M; Peters C; Reinheckel T. 2006. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 66(10):5242-50. [PubMed: 16707449] [MGI Ref ID J:109056]
Versteeg HH; Schaffner F; Kerver M; Ellies LG; Andrade-Gordon P; Mueller BM; Ruf W. 2008. Protease-activated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res 68(17):7219-27. [PubMed: 18757438] [MGI Ref ID J:138924]
Vervoort VS; Lu M; Valencia F; Lesperance J; Breier G; Oshima R; Pasquale EB. 2008. A novel Flk1-TVA transgenic mouse model for gene delivery to angiogenic vasculature. Transgenic Res 17(3):403-15. [PubMed: 18027100] [MGI Ref ID J:134089]
Vomachka AJ; Pratt SL; Lockefeer JA; Horseman ND. 2000. Prolactin gene-disruption arrests mammary gland development and retards T-antigen-induced tumor growth. Oncogene 19(8):1077-84. [PubMed: 10713693] [MGI Ref ID J:61017]
Wan Y; Emtage P; Foley R; Carter R; Gauldie J. 1999. Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralizing immunity and induce effective tumor regression. Int J Oncol 14(4):771-6. [PubMed: 10087328] [MGI Ref ID J:54273]
Wang S; Yuan Y; Liao L; Kuang SQ; Tien JC; O'Malley BW; Xu J. 2009. Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc Natl Acad Sci U S A 106(1):151-6. [PubMed: 19109434] [MGI Ref ID J:143510]
Webster MA; Hutchinson JN; Rauh MJ; Muthuswamy SK; Anton M; Tortorice CG; Cardiff RD; Graham FL; Hassell JA; Muller WJ. 1998. Requirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol 18(4):2344-59. [PubMed: 9528804] [MGI Ref ID J:56327]
Webster MA; Martin-Soudant N; Nepveu A; Cardiff RD; Muller WJ. 1998. The induction of uterine leiomyomas and mammary tumors in transgenic mice expressing polyomavirus (PyV) large T (LT) antigen is associated with the ability of PyV LT antigen to form specific complexes with retinoblastoma and CUTL1 family members. Oncogene 16(15):1963-72. [PubMed: 9591780] [MGI Ref ID J:56288]
Welm AL; Sneddon JB; Taylor C; Nuyten DS; van de Vijver MJ; Hasegawa BH; Bishop JM. 2007. The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A 104(18):7570-5. [PubMed: 17456594] [MGI Ref ID J:121299]
White DE; Kurpios NA; Zuo D; Hassell JA; Blaess S; Mueller U; Muller WJ. 2004. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 6(2):159-70. [PubMed: 15324699] [MGI Ref ID J:92547]
Williams TM; Cheung MW; Park DS; Razani B; Cohen AW; Muller WJ; Di Vizio D; Chopra NG; Pestell RG; Lisanti MP. 2003. Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 14(3):1027-42. [PubMed: 12631721] [MGI Ref ID J:132472]
Williams TM; Medina F; Badano I; Hazan RB; Hutchinson J; Muller WJ; Chopra NG; Scherer PE; Pestell RG; Lisanti MP. 2004. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem 279(49):51630-46. [PubMed: 15355971] [MGI Ref ID J:95195]
Wong SY; Crowley D; Bronson RT; Hynes RO. 2008. Analyses of the role of endogenous SPARC in mouse models of prostate and breast cancer. Clin Exp Metastasis 25(2):109-18. [PubMed: 18058030] [MGI Ref ID J:133592]
Wyckoff JB; Wang Y; Lin EY; Li JF; Goswami S; Stanley ER; Segall JE; Pollard JW; Condeelis J. 2007. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res 67(6):2649-56. [PubMed: 17363585] [MGI Ref ID J:120318]
Xue C; Plieth D; Venkov C; Xu C; Neilson EG. 2003. The gatekeeper effect of epithelial-mesenchymal transition regulates the frequency of breast cancer metastasis. Cancer Res 63(12):3386-94. [PubMed: 12810675] [MGI Ref ID J:83971]
Yang D; Stewart TJ; Smith KK; Georgi D; Abrams SI; Liu K. 2008. Downregulation of IFN-gammaR in association with loss of Fas function is linked to tumor progression. Int J Cancer 122(2):350-62. [PubMed: 17918178] [MGI Ref ID J:135543]
Yang H; Rouse J; Lukes L; Lancaster M; Veenstra T; Zhou M; Shi Y; Park YG; Hunter K. 2004. Caffeine suppresses metastasis in a transgenic mouse model: a prototype molecule for prophylaxis of metastasis. Clin Exp Metastasis 21(8):719-35. [PubMed: 16035617] [MGI Ref ID J:101443]
Yang L; Huang J; Ren X; Gorska AE; Chytil A; Aakre M; Carbone DP; Matrisian LM; Richmond A; Lin PC; Moses HL. 2008. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13(1):23-35. [PubMed: 18167337] [MGI Ref ID J:131064]
Zhang H; Kuang SQ; Liao L; Zhou S; Xu J. 2004. Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice. Cancer Res 64(19):7169-77. [PubMed: 15466215] [MGI Ref ID J:93653]
Zhang H; Stephens LC; Kumar R. 2006. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer. Clin Cancer Res 12(5):1479-86. [PubMed: 16533771] [MGI Ref ID J:110213]
Health & husbandry
Health & Colony Maintenance Information
Animal Health Reports
Room Number AX12
Colony Maintenance
Mating System Noncarrier x Hemizygote (Female x Male) Diet Information LabDiet® 5K52/5K67
Purchasing information
Pricing, Supply Level & Notes, Controls, General Terms & Conditions
Pricing
| Pricing for USA, Canada and Mexico shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided Individual Mouse $243.50 Female or Male Hemizygous for Tg(MMTV-PyVT)634Mul
Pairs /Price (US dollars $) Pair Genotype $297.85 Noncarrier x Hemizygous for Tg(MMTV-PyVT)634Mul
Additional Supply Details
| Pricing for International shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided Individual Mouse $316.60 Female or Male Hemizygous for Tg(MMTV-PyVT)634Mul
Pairs /Price (US dollars $) Pair Genotype $387.30 Noncarrier x Hemizygous for Tg(MMTV-PyVT)634Mul
Additional Supply Details
|
|
|
Supply Details
| Standard Supply | Repository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of approximately nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within two business days following order placement. |
|---|---|
| Supply Notes |
|
| Important Note | |
| This strain is homozygous for the retinal degeneration allele Pde6brd1. | |
Control Information
| Control | ||
|---|---|---|
| Noncarrier | ||
| 001800 FVB/NJ | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Payment Terms and Conditions
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
See Terms of Use tab for General Terms and Conditions
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
OncoMouse® requires a license from DuPont, see Licenses for Strains with OncoMouse® Technology.
For additional Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
Contact information
General inquiries
Contracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice, Products & Services Conditions of Use
"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
No Liability
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.